false 0001701108 0001701108 2026-10-26 2026-10-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 26, 2026
SPERO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| Delaware |
|
001-38266 |
|
46-4590683 |
| (State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
| 675 Massachusetts Avenue, 14th Floor |
|
|
| Cambridge, Massachusetts |
|
02139 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code (857) 242-1600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.001 par value |
|
SPRO |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(b) On October 26, 2026, Spero Therapeutics, Inc. (the “Company”) announced that Timothy Keutzer, the Company’s Chief Operating Officer, will retire from the Company effective as of December 31, 2026 (the “Effective Date”). In connection with his retirement, the Company expects to enter into a consulting arrangement with Mr. Keutzer on or about the Effective Date, pursuant to which Mr. Keutzer will provide advisory services to the Company in support of the transition until approximately February 28, 2027, unless earlier terminated by either party on fifteen days’ prior written notice (the “Consulting Period”). Pursuant to the terms of the Consulting Agreement, Mr. Keutzer will be paid an hourly rate for his services during the Consulting Period. Mr. Keutzer’s retirement follows 11 years of dedicated service, leadership and significant contributions to the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
| Date: October 27, 2026 |
|
SPERO THERAPEUTICS, INC. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Esther Rajavelu |
|
|
|
|
|
|
Esther Rajavelu |
|
|
|
|
|
|
Chief Executive Officer and Chief Financial Officer |
